Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00429754
Recruitment Status : Withdrawn (change of study population and chemotherapeutic regimen)
First Posted : February 1, 2007
Last Update Posted : January 26, 2016
Merck Sharp & Dohme Corp.
Information provided by:
Radboud University

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Primary Completion Date : No date given
  Study Completion Date : September 2008